Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBERNARDI, M. A.
dc.contributor.authorLOGULLO, A. F.
dc.contributor.authorPASINI, F. S.
dc.contributor.authorNONOGAKI, S.
dc.contributor.authorBLUMKE, C.
dc.contributor.authorSOARES, F. A.
dc.contributor.authorBRENTANI, M. M.
dc.date.accessioned2013-07-30T15:20:15Z
dc.date.available2013-07-30T15:20:15Z
dc.date.issued2012
dc.description.abstractThis study aimed to identify the CD24 and CD44 immunophenotypes within invasive ductal breast carcinoma (I DC) subgroups defined by immunohistochesmistry markers and to determine its influence on prognosis as well as its association with the expression of Ki-67, cytokeratins (CK5 and CK 18) and claudin-7. Immunohistochemical expression of CD44 and CD24 alone or in combination was investigated in 95 IDC cases arranged in a tissue microarray (TMA). The association with subgroups defined as luminal A and B; HER2 rich and triple negative, or with the other markers and prognosis was analyzed. CD44(+)/CD24(-) and CD44(-)/CD24(+) were respectively present in 8.4% and 16.8% of the tumors, a lack of both proteins was detected in 6.3%, while CD441(-)/CD24(+) was observed in 45.3% of the tumors. Although there was no significant correlation between subgroups and different phenotypes, the CD44(+)/CD24(-) phenotype was more common in the basal subgroups but absent in HER2 tumors, whereas luminal tumors are enriched in CD44(-)/CD24(+) and CD44(+)/CD24(+) cells. The frequency of CD44(+)/CD24(-) or CD44(-)/CD24(+) was not associated with clinical characteristics or biological markers. There was also no significant association of these phenotypes with the event free (DFS) and overall survival (OS). Single CD44(+) was evident in 57.9% of the tumors and was marginally associated to grading and not to any other tumor characteristics as well as OS and DFS. CD24(+) was positive in 74.7% of the tumors, showing a significant association with estrogen receptor, progesterone receptor and Ki-67 and a marginal association with CKI8 and claudin-7. Expression of claudin-7 and Ki-67 did not associate with the cancer subgroups, while a positive association between CK18 and the luminal subgroups was found (P=0.03). CK5, CK18 and Ki-67 expression had no influence in OS or DFS. Single CD24(+) (P=0.07) and claudin-7 positivity (P=0.05) were associated with reduced time of recurrence, suggesting a contribution of these markers to aggressiveness of breast cancer.
dc.description.indexMEDLINE
dc.description.sponsorshipFAPESP
dc.description.sponsorshipCNPq
dc.identifier.citationONCOLOGY REPORTS, v.27, n.1, p.28-38, 2012
dc.identifier.doi10.3892/or.2011.1477
dc.identifier.issn1021-335X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1138
dc.language.isoeng
dc.publisherSPANDIDOS PUBL LTD
dc.relation.ispartofOncology Reports
dc.rightsopenAccess
dc.rights.holderCopyright SPANDIDOS PUBL LTD
dc.subjectcancer stem cell
dc.subjectCD24
dc.subjectCD44
dc.subjectclaudin-7
dc.subjectprognosis
dc.subjectbreast cancer subgroups
dc.subject.otherstem-cells
dc.subject.otherexpression
dc.subject.othermetastasis
dc.subject.othertumors
dc.subject.othercd44(+)/cd24(-/low)
dc.subject.otherheterogeneity
dc.subject.othercarcinomas
dc.subject.otherphenotype
dc.subject.othersurvival
dc.subject.othersubtypes
dc.subject.wosOncology
dc.titlePrognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalBERNARDI, M. A.:AC Camargo Hosp, Mastol Dept, Sao Paulo, Brazil
hcfmusp.author.externalLOGULLO, A. F.:Univ Fed Sao Paulo, Dept Pathol, Sao Paulo, Brazil
hcfmusp.author.externalNONOGAKI, S.:Adolfo Lutz Inst, Dept Pathol, Sao Paulo, Brazil
hcfmusp.author.externalBLUMKE, C.:Uninove Univ, Sao Paulo, Brazil
hcfmusp.author.externalSOARES, F. A.:AC Camargo Hosp, Mastol Dept, Sao Paulo, Brazil
hcfmusp.citation.scopus44
hcfmusp.contributor.author-fmusphcFATIMA SOLANGE PASINI
hcfmusp.contributor.author-fmusphcMARIA MITZI BRENTANI
hcfmusp.description.beginpage28
hcfmusp.description.endpage38
hcfmusp.description.issue1
hcfmusp.description.volume27
hcfmusp.lim.ref2012
hcfmusp.origemWOS
hcfmusp.origem.pubmed21956537
hcfmusp.origem.scopus2-s2.0-84855263756
hcfmusp.origem.wosWOS:000297397500004
hcfmusp.publisher.cityATHENS
hcfmusp.publisher.countryGREECE
hcfmusp.relation.referenceAbraham BK, 2005, CLIN CANCER RES, V11, P1154
hcfmusp.relation.referenceAl-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
hcfmusp.relation.referenceAllred DC, 1998, MODERN PATHOL, V11, P155
hcfmusp.relation.referenceBaumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619
hcfmusp.relation.referenceCarey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
hcfmusp.relation.referenceCheang MCU, 2009, J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
hcfmusp.relation.referenceDiaz LK, 2005, CLIN CANCER RES, V11, P3309, DOI 10.1158/1078-0432.CCR-04-2184
hcfmusp.relation.referenceDontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x
hcfmusp.relation.referenceGiatromanolaki A, 2011, MED ONCOL, V28, P745, DOI 10.1007/s12032-010-9530-3
hcfmusp.relation.referenceHill RP, 2006, CANCER RES, V66, P1891, DOI 10.1158/0008-5472.CAN-05-3450
hcfmusp.relation.referenceHoneth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108
hcfmusp.relation.referenceHwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377
hcfmusp.relation.referenceKim HJ, 2007, CANCER LETT, V258, P98, DOI 10.1016/j.canlet.2007.08.025
hcfmusp.relation.referenceKim HJ, 2011, BREAST, V20, P78, DOI 10.1016/j.breast.2010.08.001
hcfmusp.relation.referenceKlingbeil P, 2010, BREAST CANCER RES TR, V120, P95, DOI 10.1007/s10549-009-0380-7
hcfmusp.relation.referenceKristiansen G, 2003, CLIN CANCER RES, V9, P4906
hcfmusp.relation.referenceLanigan F, 2009, INT J CANCER, V124, P2088, DOI 10.1002/ijc.24159
hcfmusp.relation.referenceLim SC, 2005, PATHOL RES PRACT, V201, P479, DOI 10.1016/j.prp.2005.05.004
hcfmusp.relation.referenceMeyer MJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2449
hcfmusp.relation.referenceMyal Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/956897
hcfmusp.relation.referenceMylona E, 2008, HUM PATHOL, V39, P1096, DOI 10.1016/j.humpath.2007.12.003
hcfmusp.relation.referencePal SK, 2011, BREAST CANCER RES TR, V125, P627, DOI 10.1007/s10549-010-1293-1
hcfmusp.relation.referencePandit TS, 2009, INT J ONCOL, V35, P297, DOI 10.3892/ijo_00000340
hcfmusp.relation.referencePark SY, 2010, CLIN CANCER RES, V16, P876, DOI 10.1158/1078-0432.CCR-09-1532
hcfmusp.relation.referencePerou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
hcfmusp.relation.referencePrat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
hcfmusp.relation.referencePrat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
hcfmusp.relation.referenceSheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
hcfmusp.relation.referenceShipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
hcfmusp.relation.referenceSmalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212
hcfmusp.relation.referenceSzasz AM, 2011, CLIN EXP METASTAS, V28, P55, DOI 10.1007/s10585-010-9357-5
hcfmusp.relation.referenceWeigelt B, 2010, J PATHOL, V220, P263, DOI 10.1002/path.2648
hcfmusp.relation.referenceWeigelt B, 2009, MODERN PATHOL, V22, P1401, DOI 10.1038/modpathol.2009.112
hcfmusp.relation.referenceYang XR, 2007, CANCER EPIDEM BIOMAR, V16, P439, DOI 10.1158/1055-9965.EPI-06-0806
hcfmusp.remissive.sponsorshipCNPq
hcfmusp.remissive.sponsorshipFAPESP
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication4f744e24-e3bf-46d3-a835-2e5adf372df4
relation.isAuthorOfPublicationee6ee170-b219-4293-8f93-4cb068951318
relation.isAuthorOfPublication.latestForDiscovery4f744e24-e3bf-46d3-a835-2e5adf372df4
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_PASINI_Prognostic_significance_of_CD24_and_claudin_7_immunoexpression_2012.PDF
Tamanho:
626.69 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/24